N-But-3-enyl-succinamic acid | 852878-74-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-But-3-enyl-succinamic acid
• 英文别名: 4-(but-3-enylamino)-4-oxobutanoic acid
• CAS: 852878-74-1
• 化学式: C₈H₁₃NO₃
• 分子量: 171.196
• InChiKey: YZHICDGUELYTRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-But-3-enyl-succinamic acid 在 4-二甲氨基吡啶 、 Hoveyda-Grubbs catalyst second generation 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成
  参考文献：
  名称：

  New insights into structure–activity relationship of ipomoeassin F from its bioisosteric 5-oxa/aza analogues

  摘要：

  Ipomoeassin F, a plant-derived macrolide, exhibited single-digit nanomolar growth inhibition activity against many cancer cell lines. In this report, a series of 5-oxa/aza analogues was prepared and screened for cytotoxicity. Replacement of 5-CH2 with O/NH simplified the synthesis and led to only a small activity loss. N-methylation almost completely restored the potency. Further studies with additional 5-oxa analogues suggested, for the first time, that size and flexibility of the ring also significantly influence the bioactivity of ipomoeassin F. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.11.022
• 作为产物：
  描述：

  丁二酸酐 、 3-丁烯-1-胺 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 12.08h， 以87%的产率得到N-But-3-enyl-succinamic acid
  参考文献：
  名称：

  New insights into structure–activity relationship of ipomoeassin F from its bioisosteric 5-oxa/aza analogues

  摘要：

  Ipomoeassin F, a plant-derived macrolide, exhibited single-digit nanomolar growth inhibition activity against many cancer cell lines. In this report, a series of 5-oxa/aza analogues was prepared and screened for cytotoxicity. Replacement of 5-CH2 with O/NH simplified the synthesis and led to only a small activity loss. N-methylation almost completely restored the potency. Further studies with additional 5-oxa analogues suggested, for the first time, that size and flexibility of the ring also significantly influence the bioactivity of ipomoeassin F. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.11.022

文献信息

• Synthesis and Evaluation of Novel Substrates and Inhibitors of <i>N-</i>Succinyl-<scp>ll</scp>-diaminopimelate Aminotransferase (DAP-AT) from <i>Escherichia coli</i>
  作者：Russell J. Cox、William A. Sherwin、Lister K. P. Lam、John C. Vederas

  DOI：10.1021/ja960640v

  日期：1996.1.1

  L-glutamate as the amino group donor for its substrate, N-succinyl-R-amino- -ketopimelic acid (1a )( K m )0.18 ( 0.04 mM, kcat ) 86 ( 5s - 1 ). Progress of the reaction is monitored by spectrophotometric observation of decrease in NADPH concentration at 340 nm in a coupled enzyme assay with L-glutamate dehydrogenase (EC 1.4.1.4). Stereochemically pure 1a was synthesized as its trilithium salt by ene reaction

  N-琥珀酰-LL-二氨基庚二酸氨基转移酶 (DAP-AT) (EC 2.6.1.17) 是细菌生成 L-赖氨酸途径中的关键酶，通过五个步骤从野生型大肠杆菌中纯化至接近同质（1500 倍） ATCC 9637。这种磷酸吡哆醛 (PLP) 依赖性酶的分子量为 39.9 kDa，似乎形成活性同二聚体，并使用 L-谷氨酸作为其底物 N-琥珀酰-R-氨基--酮基酮基的氨基供体酸 (1a )( K m )0.18 ( 0.04 mM, kcat ) 86 ( 5s - 1 )。在使用 L-谷氨酸脱氢酶 (EC 1.4.1.4) 的偶联酶测定中，通过分光光度法观察 NADPH 浓度在 340 nm 处的降低来监测反应进程。通过乙醛酸甲酯与 N-琥珀酰-L-烯丙基甘氨酸甲酯 (4a) 的烯反应，然后将双键氢化，醇的 Dess-Martin 氧化和小心的氢氧化锂水解，合成立体化学纯的 1a 作为其三锂盐。类似的方法允许合成一系列具有不同
• [EN] MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF<br/>[FR] LACTAMES MACROCYCLIQUES ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：NOVARTIS AG

  公开号：WO2005049585A1

  公开（公告）日：2005-06-02

  The present invention relates to novel macrocyclic compounds of the formula (I) wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharma­ceutical compositions comprising them.

  本发明涉及以下式（I）的新型大环化合物，其中R1、R2、R3、U、V、W、X、Y、Z和n如规范中所定义，大环环中包含的环原子数为14、15、16或17，以自由碱形式或酸盐形式存在，以及它们的制备方法，用作药物的用途，以及包含它们的药物组合物。
• Macrocyclic lactams and pharmaceutical use thereof
  申请人：Auberson Yves

  公开号：US20070072792A1

  公开（公告）日：2007-03-29

  The present invention relates to novel macrocyclic compounds of the formula wherein R 1 , R 2 , R 3 , U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

  本发明涉及到新型大环化合物，其化学式为R1、R2、R3、U、V、W、X、Y、Z和n在规范中定义，该大环中包含的环原子数为14、15、16或17，以自由碱基形式或酸加成盐形式存在，以及它们的制备方法、它们作为药物的用途以及包含它们的药物组成物。
• Macrocyclic Lactams and Pharmaceutical Use Thereof
  申请人：AUBERSON Yves

  公开号：US20100022500A1

  公开（公告）日：2010-01-28

  The present invention relates to novel macrocyclic compounds of the formula wherein R 1 , R 2 , R 3 , U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

  本发明涉及新型大环化合物，其化学式为R1，R2，R3，U，V，W，X，Y，Z和n如规范中所定义，大环环中包括的环原子数为14，15，16或17，以游离碱形式或酸盐形式存在，涉及其制备、作为药物的使用以及包括它们的药物组成物。
• MACROCYCLIC LACTAMS AND PHARMACEUTICAL USE THEREOF
  申请人：Novartis AG

  公开号：EP1682521A1

  公开（公告）日：2006-07-26